Change over period: —
NSE · AARTIPHARM
AARTIPHARM
-0.2% from the 52-week high · +71.2% above the low
Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
The short version. AARTIPHARM reported revenue of ₹610 crore for Sep 2026, up 45.9% from a year earlier. Net profit was ₹71 crore (up 144.8% year on year). Return on equity was 8.2% in Mar 2026. Promoter holding was 39.66% in Sep 2026, down 4.99 points over 8 quarters.
1 · The price
How has the stock traded?
AARTIPHARM trades 0.2% below its 52-week high and 71.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹610 cr.
Sep 2026 net profit of ₹71 cr.
4.9 pts higher than a year earlier.
Revenue compounded at -2.1% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 610 | 536 | 583 | 432 | 418 | 386 | 564 | 538 |
| Net profit | 71 | 76 | 61 | 48 | 29 | 50 | 88 | 74 |
| Net margin % | 11.7 | 14.2 | 10.5 | 11.1 | 6.8 | 12.8 | 15.7 | 13.8 |
| EPS (₹) | 7.88 | 8.4 | 6.74 | 5.29 | 3.15 | 5.46 | 9.75 | 8.16 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 1819 | 2115 | 1853 | 1945 |
| Net profit | 175 | 272 | 216 | 193 |
| Net margin % | 9.6 | 12.9 | 11.7 | 9.9 |
| EPS (₹) | 19.27 | 30.06 | 23.88 | 21.35 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 8.2% in Mar 2026; debt to equity is 0.32.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 8.2 | 13.7 | 12.3 | 12.4 |
| Return on capital % | 10.7 | 17.2 | 16.8 | 17.2 |
| EBITDA margin % | 20.6 | 22.3 | 21.1 | 17.7 |
| Net margin % | 9.6 | 12.8 | 11.7 | 9.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -2.1% | — |
| Profit CAGR | -3.4% | — |
4 · The owners
Who holds it, and are they adding?
Down 4.99 pts over 8 quarters.
Down 0.49 pts over 8 quarters.
Down 1.96 pts over 8 quarters.
+7 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.65 | 44.29 | 43.72 | 42.88 | 43.1 | 43.08 | 42.86 | 39.66 | -4.99 |
| FII | 8.64 | 7.36 | 7.35 | 8.02 | 7.68 | 8.39 | 8.17 | 8.15 | -0.49 |
| DII | 10.36 | 7.53 | 7.79 | 6.96 | 7.66 | 7.41 | 7.22 | 8.4 | -1.96 |
| Public | 36.33 | 40.81 | 41.12 | 42.13 | 41.54 | 41.11 | 41.74 | 43.78 | +7.45 |
Mutual fund holdings · Oct 2026
17 schemes hold this stock
10 the month before.
- Unifi Flexi Cap Fund3.11% of NAV
- UNION ACTIVE MOMENTUM FUND1.82% of NAV
- WhiteOak Capital Pharma and Healthcare Fund1.06% of NAV
- UTI - Healthcare Fund0.91% of NAV
- Motilal Oswal Nifty Microcap 250 Index Fund0.55% of NAV
- Taurus Flexi Cap Fund0.54% of NAV
- Motilal Oswal BSE Healthcare ETF0.28% of NAV
- Bandhan BSE Healthcare Index Fund0.28% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AARTIPHARM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about AARTIPHARM
What is the AARTIPHARM share price?
AARTIPHARM (AARTIPHARM) last closed at ₹1,013.90, up 0.05% on the day. Its 52-week range is ₹591.95 to ₹1,015.90.
What is the market cap of AARTIPHARM?
AARTIPHARM has a market capitalisation of about ₹9,173 crore. Its price-to-earnings ratio is 37.9.
How are AARTIPHARM's latest results?
AARTIPHARM reported revenue of ₹610 crore for Sep 2026, up 45.9% from a year earlier. Net profit was ₹71 crore (up 144.8% year on year). Return on equity was 8.2% in Mar 2026. Promoter holding was 39.66% in Sep 2026, down 4.99 points over 8 quarters.
Who owns AARTIPHARM?
As of Sep 2026, shareholding was: Promoter 39.66%, FII 8.15%, DII 8.4%, Public 43.78%.
How many mutual funds hold AARTIPHARM?
17 mutual fund schemes held AARTIPHARM in October 2026. That compares with 10 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 16 Feb 2026 · Interim Dividend - Rs. 1.5
- 15 Sep 2025 · Final Dividend - Rs. 2.5
- 14 Feb 2025 · Interim Dividend - Rs. 2.5
- 31 Jul 2024 · Final Dividend - Rs. 1
- 16 Feb 2024 · Interim Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.